Social media

How do patient-led organisations help bring therapies to families faster? Our live webinar gathers relentless leaders to explore real world examples of patient-led innovation reshaping drug development and regulatory str...

Flow cytometry is rapidly evolving - driven by high parameter and spectral technologies, smarter data analytics and global standardisation efforts. This Spotlight hosted by Bioanalysis Zone brings together leading expe...

Flow cytometry is rapidly evolving - driven by high parameter and spectral technologies, smarter data analytics and global standardisation efforts. This Spotlight hosted by Bioanalysis Zone brings together leading expe...

Understanding how clinical trials are delivered starts with clarity on the roles that shape them. Our latest blog explains how sponsors set the research agenda and retain oversight, how CROs manage operational delivery...

Understanding how clinical trials are delivered starts with clarity on the roles that shape them. Our latest blog explains how sponsors set the research agenda and retain oversight, how CROs manage operational delivery...

AI enabled SaMD is evolving quickly. But are we addressing model bias fast enough? Our latest blog explores how bias creeps into datasets and what developers must do to avoid perpetuating disparities in healthcare. - Im...

Regulatory change is coming to pediatric therapeutics. The EMA proposed a new MoA PIP requirement that could transform pediatric drug development and create an influx of more meaningful therapies. Learn from ICON exp...

Mechanism over indication? EMA’s upcoming MoA PIP requirement signals a major regulatory shift. Read lessons learned from the US’s RACE Act and how the MoA requirements could impact your drug development strategy: http...

ICON proudly supports International Childhood Cancer Day, reaffirming our commitment to advancing research and improving outcomes for children, survivors, and families affected by childhood cancer. In the past 5 years,...

ICON is committed to bringing safe, effective, pediatric-tested treatments to children. In the past 5 years, we have participated in 423 clinical studies, including 22 malignant haematology and 18 oncology/solid tumour s...

As digital endpoints gain regulatory traction, sponsors who invest in endpoint strategy and validation today will be better positioned to run faster, more inclusive trials tomorrow. Digital health technologies are enabli...

As digital endpoints gain regulatory traction, sponsors who invest in endpoint strategy and validation today will be better positioned to run faster, more inclusive trials tomorrow. Digital health technologies are enabli...